{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T01:56:11Z","timestamp":1774403771212,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,12,11]],"date-time":"2013-12-11T00:00:00Z","timestamp":1386720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,12,11]],"date-time":"2013-12-11T00:00:00Z","timestamp":1386720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Nutr"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1038\/ejcn.2013.253","type":"journal-article","created":{"date-parts":[[2013,12,11]],"date-time":"2013-12-11T09:54:56Z","timestamp":1386755696000},"page":"146-152","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["The effects of second-generation antipsychotics on food intake, resting energy expenditure and physical activity"],"prefix":"10.1038","volume":"68","author":[{"given":"C","family":"Cuerda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Velasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Merch\u00e1n-Naranjo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Garc\u00eda-Peris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Arango","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,12,11]]},"reference":[{"key":"BFejcn2013253_CR1","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1176\/ps.2006.57.12.1693","volume":"57","author":"RR Aparasu","year":"2006","unstructured":"Aparasu RR, Bhatara V . Antipsychotic use and expenditure in the United States. Psychiatr Serv 2006; 57: 1693.","journal-title":"Psychiatr Serv"},{"key":"BFejcn2013253_CR2","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1542\/peds.2007-2008","volume":"121","author":"F Rani","year":"2008","unstructured":"Rani F, Murray ML, Byrne PJ, Wong ICK . Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics 2008; 121: 1002\u20131009.","journal-title":"Pediatrics"},{"key":"BFejcn2013253_CR3","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1001\/archgenpsychiatry.2012.647","volume":"69","author":"M Olfson","year":"2012","unstructured":"Olfson M, Blanco C, Liu SM, Wang S, Correll CU . National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry 2012; 69: 1247\u20131256.","journal-title":"Arch Gen Psychiatry"},{"key":"BFejcn2013253_CR4","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1192\/bjp.bp.111.104257","volume":"200","author":"S Ilyas","year":"2012","unstructured":"Ilyas S, Moncrieff J . Trends in prescriptions and costs of drugs for mental disorders in England, 1998\u20132010. Br J Psychiatry 2012; 200: 393\u2013398.","journal-title":"Br J Psychiatry"},{"key":"BFejcn2013253_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1185\/030079906X158075","volume":"23","author":"RR Aparasu","year":"2007","unstructured":"Aparasu RR, Bhatara V . Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003\u20132004. Curr Med Res Opin 2007; 23: 49\u201356.","journal-title":"Curr Med Res Opin"},{"key":"BFejcn2013253_CR6","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.euroneuro.2010.07.002","volume":"21","author":"D Fraguas","year":"2011","unstructured":"Fraguas D, Correll CU, Merch\u00e1n-Naranjo J, Rapado-Castro M, Parellada M, Moreno C et al. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum diseases: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol 2011; 21: 621\u2013645.","journal-title":"Eur Neuropsychopharmacol"},{"key":"BFejcn2013253_CR7","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209\u20131223.","journal-title":"N Engl J Med"},{"key":"BFejcn2013253_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0920-9964(98)00105-4","volume":"35","author":"S Leucht","year":"1999","unstructured":"Leucht S, Pitschel-Walz G, Abraham D, Kissling W . Efficacy and extrapyramidal side-effects of the new antipsichotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a metaanalysis of randomized controlled trials. Schizophr Res 1999; 35: 51\u201368.","journal-title":"Schizophr Res"},{"key":"BFejcn2013253_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1192\/bjp.bp.107.037218","volume":"192","author":"S Lewis","year":"2008","unstructured":"Lewis S, Lieberman J . CATIE and CUtLASS: can we handle the truth? Br J Psych 2008; 192: 161\u2013163.","journal-title":"Br J Psych"},{"key":"BFejcn2013253_CR10","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1176\/ps.2008.59.5.523","volume":"59","author":"WT Carpenter","year":"2008","unstructured":"Carpenter WT, Buchanan RW . Lessons to take home from CATIE. Psychiatr Serv 2008; 59: 523\u2013525.","journal-title":"Psychiatr Serv"},{"key":"BFejcn2013253_CR11","doi-asserted-by":"publisher","first-page":"596","DOI":"10.2337\/diacare.27.12.3024","volume":"27","author":"NG Clark","year":"2004","unstructured":"Clark NG . Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596\u2013601.","journal-title":"Diabetes Care"},{"key":"BFejcn2013253_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00023210-200519001-00001","volume":"19","author":"JW Newcomer","year":"2005","unstructured":"Newcomer JW . Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19: 1\u201393.","journal-title":"CNS Drugs"},{"key":"BFejcn2013253_CR13","first-page":"22","volume":"62","author":"DB Allison","year":"2001","unstructured":"Allison DB, Casey DE . Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001; 62: 22\u201331.","journal-title":"J Clin Psychiatry"},{"key":"BFejcn2013253_CR14","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/j.1463-1326.2004.00413.x","volume":"7","author":"AJ Goudie","year":"2005","unstructured":"Goudie AJ, Cooper D, Halford JCG . Antipsychotic-induced weight gain. Diabetes Obes Metab 2005; 7: 478\u2013487.","journal-title":"Diabetes Obes Metab"},{"key":"BFejcn2013253_CR15","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1176\/appi.ajp.159.6.1055","volume":"159","author":"D Gothelf","year":"2002","unstructured":"Gothelf D, Falk B, Singer P, Kairi M, Phillip M, Zigel L et al. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 2002; 159: 1055\u20131057.","journal-title":"Am J Psychiatry"},{"key":"BFejcn2013253_CR16","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.clnu.2011.03.007","volume":"30","author":"C Cuerda","year":"2011","unstructured":"Cuerda C, Merchan-Naranjo J, Velasco C, Gutierrez A, Leiva M, de Castro MJ et al. Influence of resting energy expenditure on weight gain in adolescents taking second-generation antipsychotics. Clin Nutr 2011; 30: 616\u2013623.","journal-title":"Clin Nutr"},{"key":"BFejcn2013253_CR17","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1001\/jama.2009.1549","volume":"302","author":"CU Correll","year":"2009","unstructured":"Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK . Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302: 1765\u20131773.","journal-title":"JAMA"},{"key":"BFejcn2013253_CR18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.molmed.2010.10.010","volume":"17","author":"CU Correll","year":"2011","unstructured":"Correll CU, Lencz T, Malhotra AK . Antipsychotic drugs and obesity. Trends Mol Med 2011; 17: 97\u2013107.","journal-title":"Trends Mol Med"},{"key":"BFejcn2013253_CR19","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/01.jcp.0000177549.36585.29","volume":"25","author":"JL Roerig","year":"2005","unstructured":"Roerig JL, Mitchell JE, Zwaan M, Crosby RD, Gosnell BA, Steffen KJ et al. A comparison of the effects of olanzapine and risperidone versus placebo on eating behaviours. J Clin Psychopharmacol 2005; 25: 413\u2013418.","journal-title":"J Clin Psychopharmacol"},{"key":"BFejcn2013253_CR20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/oby.2010.6","volume":"18","author":"RJ Fountaine","year":"2010","unstructured":"Fountaine RJ, Taylor AE, Mancuso JP, Greenway FL, Byerley LO, Smith SR et al. Increased food intake and energy expenditure following administration of olanzapine to healthy men. Obesity 2010; 18: 46\u201351.","journal-title":"Obesity"},{"key":"BFejcn2013253_CR21","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.2337\/db13-0430","volume":"62","author":"KL Teff","year":"2013","unstructured":"Teff KL, Rickels MR, Grudziak J, Fuller C, Nguyen H-L, Rickels K . Antipsychotic-induced insulin resistance and postprandial hormonal dysregualtion independent of weight gain or psychiatric disease. Diabetes 2013; 62: 3232\u20133240.","journal-title":"Diabetes"},{"key":"BFejcn2013253_CR22","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1038\/oby.2008.277","volume":"16","author":"M Blouin","year":"2008","unstructured":"Blouin M, Tremblay A, Jalbert ME, Venables H, Bouchard RH, Roy MA et al. Adiposity and eating behaviors in patients under second generation antipsychotics. Obesity 2008; 16: 1780\u20131787.","journal-title":"Obesity"},{"key":"BFejcn2013253_CR23","first-page":"33","volume":"22","author":"DC Henderson","year":"2010","unstructured":"Henderson DC, Sharma B, Fan X, Copeland PM, Borba CP, Freudenreich O et al. Dietary saturated fat intake and glucose metabolism impairments in nondiabetic, nonobese patietns with schizophrenia on olanzapine or risperidone. Ann Clin Psychiatry 2010; 22: 33\u201342.","journal-title":"Ann Clin Psychiatry"},{"key":"BFejcn2013253_CR24","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/YIC.0b013e32832b6bf6","volume":"24","author":"O Sentissi","year":"2009","unstructured":"Sentissi O, Viala A, Bourdel MC, Kaminski F, Bellisle F, Oli\u00e9 JP et al. Impact of antipsychotic treatments on the motivation to eat: preliminary results in 153 schizophrenic patients. Int Clin Psychopharmacol 2009; 24: 257\u2013264.","journal-title":"Int Clin Psychopharmacol"},{"key":"BFejcn2013253_CR25","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/1471-244X-10-72","volume":"10","author":"M Case","year":"2010","unstructured":"Case M, Treuer T, Karagianis J, Hoffmann VP . The potential role of appetite in predicting weight changes during treatment with olanzapine. BMC Psychiatry 2010; 10: 72\u201380.","journal-title":"BMC Psychiatry"},{"key":"BFejcn2013253_CR26","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1097\/jcp.0b013e31815a8872","volume":"27","author":"M Kluge","year":"2007","unstructured":"Kluge M, Schuld A, Himmerich H, Dalal M, Schacht A, Wehmeier PM et al. Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized doubled-blind study. J Clin Psychopharmacol 2007; 27: 662\u2013666.","journal-title":"J Clin Psychopharmacol"},{"key":"BFejcn2013253_CR27","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00702-002-0792-6","volume":"110","author":"FM Theisen","year":"2003","unstructured":"Theisen FM, Linden A, Kong IR, Martin M, Remschmidt H, Hebebrand J . Spectrum of binge eating aymptomatology in patients treated with clozapine and olanzapine. J Neural Transm 2003; 110: 111\u2013121.","journal-title":"J Neural Transm"},{"key":"BFejcn2013253_CR28","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1210\/jc.2008-1815","volume":"95","author":"S Vidarsdottir","year":"2010","unstructured":"Vidarsdottir S, de Leeuw van Weenen JE, Fr\u00f6lich M, Roelfsema F, Romijn JA, Piel H . Effects of olanzapine and haloperidol on the metabolic status of healthy men. J Clin Endocrinol Metab 2010; 95: 118\u2013125.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFejcn2013253_CR29","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.4088\/JCP.08m04654yel","volume":"71","author":"S Vidarsdottir","year":"2010","unstructured":"Vidarsdottir S, Vlug P, Roelfsema F, Fr\u00f6lich M, Pijl H . Orally disintegrating and oral standard olanzapine tablets similarly elevate the Homeostatic Model Assessment of Insulin Resistance Index and plasma triglyceride levels in 12 healthy men: a randomized crossover study. J Clin Psychiatry 2010; 71: 1205\u20131211.","journal-title":"J Clin Psychiatry"},{"key":"BFejcn2013253_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1600-0447.2005.00700.x","volume":"114","author":"BM Nilsson","year":"2005","unstructured":"Nilsson BM, Forslund AH, Olsson RM, Hambraeus L, Wiesel FA . Differences in resting energy expenditure and body composition between patients with schizophrenia and healthy controls. Acta Psychiatr Scand 2005; 114: 27\u201335.","journal-title":"Acta Psychiatr Scand"},{"key":"BFejcn2013253_CR31","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.jada.2005.01.005","volume":"105","author":"JK Sharpe","year":"2005","unstructured":"Sharpe JK, Byrne NM, Stedman TJ, Hills AP . Resting energy expenditure is lower than predicted in people taking atypical antipsychotic medication. J Am Diet Assoc 2005; 105: 612\u2013615.","journal-title":"J Am Diet Assoc"},{"key":"BFejcn2013253_CR32","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.nut.2008.08.006","volume":"25","author":"M Skouroliakou","year":"2009","unstructured":"Skouroliakou M, Giannopolou I, Kostara C, Vasilopoulou M . Comparison of predictive equations for resting metabolic rate in obese psychiatric patients taking olanzapine. Nutrition 2009; 25: 188\u2013193.","journal-title":"Nutrition"},{"key":"BFejcn2013253_CR33","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/j.1399-5618.2007.00426.x","volume":"9","author":"I Soreca","year":"2007","unstructured":"Soreca I, Mauri M, Castrogiovanni S, Simoncini M, Cassano GB . Measured and expected resting energy expenditure in patients with bipolar disorder on maintenance treatment. Bipolar Disord 2007; 9: 784\u2013788.","journal-title":"Bipolar Disord"},{"key":"BFejcn2013253_CR34","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1055\/s-2002-31521","volume":"35","author":"M Virkkunen","year":"2002","unstructured":"Virkkunen M, Wahlbeck K, Rissanen A, Naukkarinen H, Franssila-Kallunki A . Decrease of energy expenditure causes weight increase in olanzapine treatment\u2014a case study. Pharmacopsychiatry 2002; 35: 124\u2013126.","journal-title":"Pharmacopsychiatry"},{"key":"BFejcn2013253_CR35","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0920-9964(03)00190-7","volume":"66","author":"RM Procyshyn","year":"2004","unstructured":"Procyshyn RM, Chau A, Tse G . Clozapine\u2019s effects on body weight and resting metabolic rate: a case series. Schizophr Res 2004; 66: 159\u2013162.","journal-title":"Schizophr Res"},{"key":"BFejcn2013253_CR36","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1176\/appi.ajp.162.1.118","volume":"162","author":"KA Graham","year":"2005","unstructured":"Graham KA, Perkins DO, Edwards LJ, Barrier RC, Lieberman JA, Harp JB . Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry 2005; 162: 118\u2013123.","journal-title":"Am J Psychiatry"},{"key":"BFejcn2013253_CR37","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1600-0447.2008.01342.x","volume":"119","author":"JK Sharpe","year":"2009","unstructured":"Sharpe JK, Stedman TJ, Byrne NM, Hills AP . Low-fat oxidation may be a factor in obesity among men with schizophrenia. Acta Psychiatr Scand 2009; 119: 451\u2013456.","journal-title":"Acta Psychiatr Scand"},{"key":"BFejcn2013253_CR38","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1080\/j.1440-1614.2006.01888.x","volume":"40","author":"JK Sharpe","year":"2006","unstructured":"Sharpe JK, Stedman TJ, Byrne NM, Wishart C, Hills AP . Energy expenditure and physical activity in clozapine use: implications for weight management. Aust N Z J Psychiatry 2006; 40: 810\u2013814.","journal-title":"Aust N Z J Psychiatry"},{"key":"BFejcn2013253_CR39","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.schres.2006.09.025","volume":"90","author":"J Bobes","year":"2007","unstructured":"Bobes J, Arango C, Aranda P, Carmena C, Garcia-Garcia M, Rejas J . Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS study. Schizophr Res 2007; 90: 162\u2013173.","journal-title":"Schizophr Res"},{"key":"BFejcn2013253_CR40","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1176\/ajp.2007.164.7.1050","volume":"164","author":"JP McEvoy","year":"2007","unstructured":"McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007; 164: 1050\u20131060.","journal-title":"Am J Psychiatry"},{"key":"BFejcn2013253_CR41","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","volume":"371","author":"RS Kahn","year":"2008","unstructured":"Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. Lancet 2008; 371: 1085\u20131097.","journal-title":"Lancet"},{"key":"BFejcn2013253_CR42","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/sj.npp.1300027","volume":"28","author":"WK Kroeze","year":"2003","unstructured":"Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003; 28: 519\u2013526.","journal-title":"Neuropsychopharmacology"},{"key":"BFejcn2013253_CR43","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/10401230600614538","volume":"18","author":"DC Henderson","year":"2006","unstructured":"Henderson DC, Borba CP, Daley TB, Boxill R, Nguyen DD, Culhane MA et al. Dietary intake profile of patients with schizophrenia. Ann Clin Psychiatry 2006; 18: 99\u2013105.","journal-title":"Ann Clin Psychiatry"},{"key":"BFejcn2013253_CR44","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1017\/S0033291798008186","volume":"29","author":"S Brown","year":"1999","unstructured":"Brown S, Birtwistle J, Roe L, Thompson C . The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999; 29: 697\u2013701.","journal-title":"Psychol Med"},{"key":"BFejcn2013253_CR45","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1136\/bmj.317.7161.784","volume":"317","author":"R McCreadie","year":"1998","unstructured":"McCreadie R, Macdonald E, Blacklock C, Tilak-Singh D, Wiles D, Halliday J et al. Dietary intake of schizophrenic patients in Nithsdale, Scotland: case\u2013control study. BMJ 1998; 317: 784\u2013785.","journal-title":"BMJ"},{"key":"BFejcn2013253_CR46","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/10284150400010012","volume":"7","author":"C Stokes","year":"2004","unstructured":"Stokes C, Peet M . Dietary sugar and polyunsaturated fatty acid consumption as predictors of severity of schizophrenia symptoms. Nutr Neurosci 2004; 7: 247\u2013249.","journal-title":"Nutr Neurosci"},{"key":"BFejcn2013253_CR47","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.pharmthera.2010.04.008","volume":"127","author":"R Coccurello","year":"2010","unstructured":"Coccurello R, Moles A . Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design. Pharmacol Ther 2010; 127: 210\u2013251.","journal-title":"Pharmacol Ther"},{"key":"BFejcn2013253_CR48","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.schres.2007.11.026","volume":"100","author":"H Jin","year":"2008","unstructured":"Jin H, Meyer JM, Mudaliar S, Jeste DV . Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr Res 2008; 100: 70\u201385.","journal-title":"Schizophr Res"},{"key":"BFejcn2013253_CR49","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1093\/schbul\/sbm141","volume":"34","author":"O Sentissi","year":"2008","unstructured":"Sentissi O, Epelbaum J, Oli\u00e9 JP, Poirier MF . Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review. Schizophr Bull 2008; 34: 1189\u20131199.","journal-title":"Schizophr Bull"},{"key":"BFejcn2013253_CR50","first-page":"430","volume":"26","author":"AC Pinheiro Volp","year":"2011","unstructured":"Pinheiro Volp AC, Esteves de Oliveira FC, Duarte Moreira Alves R, Esteves EA, Bressan J . Energy expenditure: components and evaluation methods. Nutr Hosp 2011; 26: 430\u2013440.","journal-title":"Nutr Hosp"},{"key":"BFejcn2013253_CR51","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1093\/ajcn\/34.9.1816","volume":"34","author":"P Webb","year":"1981","unstructured":"Webb P . Energy expenditure and fat-free mass in men and women. Am J Clin Nutr 1981; 34: 1816\u20131826.","journal-title":"Am J Clin Nutr"},{"key":"BFejcn2013253_CR52","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1093\/ajcn\/49.5.968","volume":"49","author":"E Ravussin","year":"1989","unstructured":"Ravussin E, Bogardus C . Relationship of genetics, age, and physical fitness to daily energy expenditure and fuel utilization. Am J Clin Nutr 1989; 49: 968\u2013975.","journal-title":"Am J Clin Nutr"},{"key":"BFejcn2013253_CR53","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1177\/014860710302700121","volume":"27","author":"SA McClave","year":"2003","unstructured":"McClave SA, Lowen CC, Kleber MJ, McConnell JW, Jung LY, Goldsmith LJ . Clinical use of the respiratory quotient obtained from indirect calorimetry. J Parenter Enteral Nutr 2003; 27: 21\u201326.","journal-title":"J Parenter Enteral Nutr"}],"container-title":["European Journal of Clinical Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/ejcn2013253.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ejcn2013253","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ejcn2013253.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T13:51:26Z","timestamp":1648216286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ejcn2013253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,11]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["BFejcn2013253"],"URL":"https:\/\/doi.org\/10.1038\/ejcn.2013.253","relation":{},"ISSN":["0954-3007","1476-5640"],"issn-type":[{"value":"0954-3007","type":"print"},{"value":"1476-5640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,11]]},"assertion":[{"value":"7 June 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}